Presentation Repository

Investigators of the STAMPEDE study regularly disseminate status updates and results form the study in formal presentations at conferences as well as less formal presentations amongst colleagues or stakeholders to the STAMPEDE trial. Please find the repository of these presentations made with regards to STAMPEDE.

Looking to present any of this information? Then please get in touch with the STAMPEDE trial team and let us know.

 

STAMPEDE Trial Data from ESMO

EMUC 2018 - Prof Nicholas James

 

Role of Abiraterone Acetate + Prednisolone + ADT in High and Low Risk Metastatic Hormone Naïve Prostate Cancer

ESMO 2018 - Mr Alex Hoyle

 

Radiotherapy to the primary tumour for men with newly-diagnosed metastatic prostate cancer: Survival results from STAMPEDE

ESMO 2018 - Dr Christopher Parker

 

Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): long-term survival, quality-adjusted survival and cost-effectiveness analysis.

Genitourinary Cancers Symposium 2018 - Prof Nicholas James

 

Adding abiraterone for men with high-risk prostate cancer starting long-term androgen deprivation therapy: Survival results from STAMPEDE

ASCO 2017 - Prof Nicholas James

 

How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom

ASCO 2017 - Prof Nicholas James

 

Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): long-term survival, quality-adjusted survival and cost-effectiveness analysis.

ASCO 2017 - Prof Nicholas James

 

STAMPEDE / LATITUDE coverage overview

ASCO 2017 - Janssen

 

Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE

ESMO 2017 - Mr Matthew Sydes

 

Comparative data from STAMPEDE: Celecoxib and/or zoledronic acid for hormone-naïve prostate cancer

Genitourinary Cancers Symposium 2016 - Prof Nicholas James

 

Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First survival results from STAMPEDE

ASCO 2015 - Prof Nicholas James

 

Clinical Trial Design and Chemotherapy Use in Prostate Cancer: Correcting Old Mistakes, Making New Ones

ASCO 2015 - Dr Ian Tannock

STAMPEDE

Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.